Wall Street embraces health insurers after payment win; liver disease research turns to AI for trial design

Taking stock of the drug industry, from the lab to the medicine chest

April 7, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Jim Mone/AP STAT+ | Wall Street embraces health insurers after scoring Medicare Advantage payment win Insurers in Medicare Advantage will retain billions in extra taxpayer dollars next year, after the Biden administration delayed reforms. By Bob Herman STAT+ | Liver disease researchers are hoping AI can improve their trial design NASH and liver fibrosis are driven by a "multi-modal conspiracy"; the hope is that tools like ChatGPT can see patterns a human would miss. By Isabella Cueto STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions, and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman Adobe STAT+ | Digital health pioneer Pear Therapeutics files for bankruptcy The road has run out for Pear Therapeutics: the pioneering digital therapeutics company filed for chapter 11 bankruptcy on Friday and will seek to sell off its assets to pay back its creditors. Pear will terminate 170 employees, or approximately 92% of its workforce, and will continue to operate in limited capacity with 15 employees as it seeks a buyer. CEO Corey McCann has stepped down from his role, but will continue to serve on the company's board and will provide consulting services. By Mario Aguilar

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser